NSE: MEDANTA | BSE: 543654 | Sector: Healthcare / Hospitals | CMP: ₹1,232 | Market Cap: ₹33,129 Cr

Global Health (Medanta): North India Hospital Compounder, Capex Peak

Investment View: Medanta is one of the largest private multi-specialty tertiary care providers in the North and East regions of India, operating a six-hospital, 3,435-bed network anchored by the flagship Gurugram Medanta facility. FY26 revenue rose 19% YoY to ₹4,410 Cr with net profit of ₹554 Cr (EPS ₹20.70), capping a 5-year revenue CAGR of 25% and a 5-year profit CAGR of 81%. We initiate with a constructive view on the structural hospital story but flag capex intensity (₹1,089 Cr investing outflows in FY26, free cash flow negative at -₹263 Cr), margin pressure (OPM slipped from 25% in FY24 to 21% in FY26), and the rich 59.5x P/E as headwinds. Fair value ₹1,250–1,350 band — a quality compounder trading at a growth premium with capex digestion as the next 12-month catalyst.

§1 — Business Overview: The Medanta Network

Global Health Limited (the listed entity operating under the "Medanta" brand) is one of the largest private multi-specialty tertiary and quaternary care hospital chains in India, with a uniquely North-and-East-India-skewed footprint that differentiates it from peers like Apollo Hospitals (South-heavy), Fortis (North+East), and Max Healthcare (NCR-dominated). The company operates 6 hospitals under the Medanta master brand across Gurugram, Indore, Ranchi, Lucknow, Patna, and Noida, spanning a built-up area of 5.6 million square feet and supported by 3,435 installed beds (as of 30-Sep-2025). The chain engages 2,000+ doctors across 30+ medical specialties, with department heads that include some of the most credentialed clinicians in the country — a key reason Medanta commands premium realization and tier-1 patient mix.

1.1 The Medanta Origin Story

Medanta was founded in 2009 by Dr. Naresh Trehan, a globally renowned cardiac surgeon and one of India's most respected clinicians, who returned from the United States to build a hospital modeled on global best practices (often compared to Cleveland Clinic, Mayo Clinic, and Johns Hopkins). The flagship Medanta – The Medicity, Gurugram, opened in 2009 as a single ~1,250-bed facility and quickly became a destination hospital for cardiology, cardiac surgery, neurosurgery, oncology, gastroenterology, orthopedics, liver transplant, and kidney & urology — the "anchor specialties" that continue to drive the Medanta brand. Dr. Naresh Trehan remains Chairman and the clinical face of the company, supported by a professional management team led by Pankaj Sahni (Group CEO) and a strong bench of department heads who are equity-aligned through ESOPs.

1.2 Hospital Footprint & Bed Base

The Medanta footprint today is a hub-and-spoke model with Gurugram as the flagship hub and Indore, Lucknow, Patna, Ranchi, and Noida as regional spokes — the latter (Noida) being the most recent addition, commissioned in 2024. Below is the operating footprint in detail.

1.3 Specialty Mix & Clinical Differentiation

The Medanta clinical franchise is built on a "complex-care-first" positioning. Unlike single-specialty chains (e.g., Narayana Hrudayalaya for cardiac, Tata Memorial-style for oncology), Medanta deliberately concentrates on high-acuity, high-ARPOB specialties that require deep clinical talent and command premium pricing. The specialty mix is summarized below.

1.4 Leadership & Governance

The Dr. Trehan brand is a structural asset — it differentiates Medanta from peers in clinical trust and referral pull, particularly in cardiac and complex surgical work, where patients often bypass regional hospitals and travel to Gurugram Medanta specifically for the brand and the doctor.

§2 — Latest Quarter Deep Dive (Q4 FY26 / Mar 2026)

Q4 FY26 was a mixed quarter for Global Health (Medanta) — the topline beat but margin compression and a spike in interest & depreciation capped the bottom line. The headline numbers below are the foundation for our quarterly scorecard.

2.1 Headline Quarterly Numbers

2.2 Quarterly Trajectory (Last 13 Quarters)

The 13-quarter trajectory shows sequential ramp in revenue, margin volatility, and the Q4 FY26 recovery after a weak Q3 FY26 — a useful tape to decode.

2.3 Margin Bridge — Why OPM Slipped

The OPM compression from 25% in FY24 to 21% in FY26 is the single most-watched datapoint. The bridge below attributes the ~400 bps slip to identifiable factors.

2.4 Capacity Expansion Trajectory

The Medanta capex cycle is the defining feature of the FY24–FY28 story. The table below maps the bed addition plan.

2.5 ARPOB & Occupancy Trends

ARPOB (Average Revenue Per Occupied Bed) and occupancy are the two operating KPIs that determine Medanta's margin trajectory. Below is our read on the last 8 quarters and FY trends.

§3 — 5-Year Financial Performance

The FY21–FY26 period is Global Health's most consequential window: the IPO (Nov 2021, fresh issue + offer-for-sale, listed on NSE/BSE), COVID recovery, bed expansion (Patna, Noida), and margin normalization. The 10-year and 5-year tables below set the structural narrative.

3.1 Profit & Loss — 10-Year Track Record

3.2 Growth Rates — Compounding Lens

3.3 Balance Sheet — 10-Year Track Record

3.4 Cash Flow — 10-Year Track Record

3.5 Key Return Ratios — Trend

3.6 What the Numbers Tell Us

The structural read is clear: revenue has compounded at 25% over 5 years, net profit at 81% (off a low FY21 base), and balance sheet has strengthened (debt/equity peaked at 0.69x in FY22, normalized to 0.30x in FY26). The recent slip in OPM (25% → 21%) and negative FCF (₹-263 Cr) is capex-driven (Noida, Patna, Indore expansion), not a structural concern in our view — but the next 4–6 quarters will determine whether Medanta can digest capex and restore FCF positivity by FY28.

§4 — Industry & Competition: Hospital Peer Comparison

The Indian hospital industry is a ₹8–9 Lakh Crore addressable market growing at ~12–14% CAGR, with the private multi-specialty tertiary care sub-segment growing at ~15–18% as insurance penetration (PMJAY + private), lifestyle disease burden, and medical tourism drive demand-side tailwinds. Medanta competes in a 4-pillar peer set that we compare in detail below.

4.1 Peer Set Definition

4.2 Peer Financial Comparison (FY25–FY26 estimates)

4.3 Operational Peer Comparison

4.4 Strategic Positioning

4.5 Industry Tailwinds & Headwinds

§5 — DCF Valuation: Per-Bed DCF

Medanta is a capital-intensive, long-duration hospital business, so a per-bed DCF (discounted cash flow) is the most defensible valuation framework. We model per-bed cash flow generation over a 15-year horizon, normalize for occupancy and ARPOB, and discount at a hospital-sector WACC of 11%.

5.1 Key DCF Assumptions

5.2 Per-Bed DCF (FY27E–FY40E)

5.3 DCF Sensitivity

5.4 Multiple Cross-Check

5.5 Per-Bed Value Comparison vs Peers

§6 — Analyst Consensus & Brokerage View

Medanta is covered by ~18–22 sell-side analysts, with the consensus rating skewing "Buy/Add" but with divergence on near-term margin concerns. The Bloomberg/FactSet consensus shows the following distribution.

6.1 Consensus Rating Distribution

6.2 Target Price Range & Consensus

6.3 Key Sell-Side Themes

6.4 Top Brokerage Targets (Representative)

6.5 Consensus 2-Year Forward Estimates

§7 — Shareholding Pattern

The Medanta shareholding structure reflects a stable promoter base (the Trehan family + founding shareholders), growing institutional interest (FIIs + DIIs), and a wide retail float. The pattern is the most institutionally-owned in the mid-cap hospital sub-segment, a sign of quality and liquidity.

7.1 Latest Quarterly Shareholding (Mar 2026)

7.2 Yearly Shareholding Trend (4 Years)

7.3 Top Institutional Holders (Indicative)

7.4 Promoter Holding Detail

7.5 Key Observations

§8 — Key Risks: Regulatory, Capex, Execution

Medanta's risk-reward is shaped by five identifiable risks — we walk through each, quantify, and rank.

8.1 Risk Matrix

8.2 Risk Detail: Regulatory

8.3 Risk Detail: Capex & Execution

8.4 Risk Detail: Margin Pressure

8.5 Risk Detail: Competition

8.6 Risk Detail: Valuation

8.7 Downside Scenario

§9 — Investment Thesis: Quality Compounder, Capex Peak

The Medanta investment case rests on three structural pillars and two tactical considerations. We close with a rating, target, and time-horizon view.

9.1 Pillar 1: Brand Moat & Clinical Talent

9.2 Pillar 2: Bed Expansion & Operating Leverage

9.3 Pillar 3: Structural Industry Tailwinds

9.4 Tactical: Capex Peak in FY26, FCF Inflection FY28

9.5 Tactical: Valuation Re-Rating Path

9.6 Final Rating, Target, and Time Horizon

9.7 Who Should Buy, Who Should Wait

9.8 Key Metrics to Monitor (Quarterly)

9.9 Bull / Base / Bear Summary

9.10 Closing View

Global Health (Medanta) is a quintessential quality compounder at a structural-growth crossroads: capex peak in FY26, FCF inflection by FY28, and a brand moat anchored by Dr. Naresh Trehan that is rare, if not unique, in Indian healthcare. The 59.5x P/E is full — but not expensive if 20%+ profit CAGR sustains over FY26–FY29E. BUY with a 24–36 month horizon, accumulate on dips below ₹1,150, and trim above ₹1,450. The next 4 quarters (Q1–Q4 FY27) are the decisive window: watch Noida occupancy, OPM trajectory, and capex run-rate as the trinity of signals for thesis confirmation or revision.

Appendix: Quick-Reference Scorecard